Bitter medicine. New regulations aim to address the dearth of clinical safety trials for drugs used in children

Journal Title: EMBO Reports - Year 2008, Vol 9, Issue 6

Abstract

Authors and Affiliations

Mark Greener

Keywords

Related Articles

The La-related protein LARP7 is a component of the 7SK ribonucleoprotein and affects transcription of cellular and viral polymerase II genes

The positive transcription elongation factor b (P-TEFb) is a heterodimeric complex composed of cyclin-dependent kinase 9 and its regulator cyclin T1/2. It stimulates transcription elongation by phosphorylation of serine...

Atrophin recruits HDAC1/2 and G9a to modify histone H3K9 and to determine cell fates

Atrophin family proteins, including the vertebrate arginine–glutamic acid dipeptide repeats protein (RERE) and Drosophila Atrophin (Atro), constitute a new class of nuclear receptor corepressors. Both RERE and At...

Assembly of the three small Tim proteins precedes docking to the mitochondrial carrier translocase

The mitochondrial intermembrane space contains a family of small Tim proteins that function as essential chaperones for protein import. The soluble Tim9–Tim10 complex transfers hydrophobic precursor proteins thro...

Have we become overly reliant on lipid rafts? Talking Point on the involvement of lipid rafts in T-cell activation

During the past decade, the lipid-raft hypothesis has focused attention on the role of membrane domains in controlling cellular functions. Among the best-studied roles of lipid rafts is the regulation of T-cell signallin...

Download PDF file
  • EP ID EP679936
  • DOI  10.1038/embor.2008.95
  • Views 26
  • Downloads 0

How To Cite

Mark Greener (2008). Bitter medicine. New regulations aim to address the dearth of clinical safety trials for drugs used in children. EMBO Reports, 9(6), -. https://europub.co.uk/articles/-A-679936